AbbVie (NYSE:ABBV) Price Target Raised to $290.00

Key Points

• Cantor Fitzgerald raised AbbVie’s price target to $290 from $285 and maintained an “overweight” rating, implying 6.87% potential upside. Analysts collectively rate the stock “Moderate Buy,” with a consensus target of $276.11.
• AbbVie shares rose 1.8% to open at $271.37, near their 12-month high of $274.94. The company recently exceeded quarterly EPS and revenue estimates, with revenue up 10.2% year over year.
• Pipeline developments remain favorable: the FDA granted breakthrough designations to telisotuzumab adizutecan, while a Phase 3 trial showed epcoritamab plus R-CHOP reduced progression or death risk by 51% in newly diagnosed diffuse large B-cell lymphoma.

AbbVie (NYSE:ABBV - Get Free Report) had its target price boosted by Cantor Fitzgerald from $285.00 to $290.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Cantor Fitzgerald's price target would indicate a potential upside of 6.87% from the stock's current price.

ABBV has been the subject of a number of other research reports. Bank of America restated a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and lifted their price target for the company from $235.00 to $300.00 in a report on Thursday, August 13th. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. HSBC raised their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Finally, Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and a consensus price target of $276.11.

AbbVie Trading Up 1.8%

ABBV stock opened at $271.37 on Thursday. The stock has a market capitalization of $479.44 billion, a price-to-earnings ratio of 76.66, a PEG ratio of 1.22 and a beta of 0.24. The firm's 50-day moving average price is $258.27 and its two-hundred day moving average price is $235.87. AbbVie has a 12-month low of $190.75 and a 12-month high of $274.94.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the firm earned $2.97 earnings per share. AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie will post 13.93 EPS for the current year.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC raised its stake in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after purchasing an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC lifted its position in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC lifted its position in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock worth $637,000 after buying an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC boosted its stake in AbbVie by 0.4% in the second quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company's stock valued at $2,996,000 after buying an additional 43 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations to AbbVie’s investigational cancer drug telisotuzumab adizutecan (Temab-A/ABBV-400), covering colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, strengthening the company’s oncology pipeline and ADC portfolio. They do not represent an approval, but investors viewed the news favorably. AbbVie Temab-A FDA Breakthrough Designations
• Positive Sentiment: AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 success could expand Epkinly’s commercial opportunity and position it as a stronger competitor to Roche’s Polivy. AbbVie Epkinly Phase 3 Results
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, implying continued upside based on the company’s pipeline and earnings outlook. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may remain focused on operating performance, guidance, and progress in replacing Humira-related revenue ahead of the release. AbbVie Upcoming Earnings
• Negative Sentiment: One analysis highlighted AbbVie’s reported payout ratio of roughly 190%, arguing that the dividend exceeds accounting earnings and could raise concerns about long-term sustainability. This is a risk for income-focused investors, although the measure can be affected by noncash charges and does not by itself indicate an imminent dividend cut. AbbVie Dividend Payout Analysis

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.